Campaign and petition email responses

Will you attend Alzheimer's Research UK's event?

As you may be aware, health is a devolved matter to the Scottish Parliament. 

The SNP commend the work done by Alzheimer’s Research UK, and their aim to find a cure for dementia. 

Recently, the Scottish Government published their new 10-year dementia strategy for Scotland “ocument/dementia-scotland-everyones-story.pdf" target="_blank" rel="noreferrer noopener">Dementia in Scotland: Everyone’s Story”. 

It makes clear the importance of a shared vision that is owned by all of us working together to deliver a better experience for people living with dementia, their families and carers. 

It builds on several years of globally-recognised public policy on dementia in Scotland and commits to ongoing reflection and learning, greater inclusion and delivery from the start. 

Last year, the Scottish Government established a National Dementia Lived Experience Panel, drawing membership from different backgrounds, experiences, and places. This Panel has worked alongside local and national government, and with wider partners, to develop this strategy. 

The Scottish Government are committed to upholding rights, civic participation, social inclusion, support and care for people living with dementia in Scotland now and in future. 

My SNP colleague, Kirsten Oswald MP, recently tabled an Early Day Motion to recognize Alzheimer Scotland and Dementia Awareness Week.    

The NHS Research Scotland Neuroprogressive and Dementia Research Network is funded by the Scottish Government to deliver cutting edge clinical research in Neuroprogressive conditions and Dementia across Scotland. For example, the network has been key to the delivery in Scotland of the UK-wide MND SMART Trial, with over 200 of the 400 total trial participants as of October 2022 enrolled in Scottish centres. 

My SNP colleague, Dr Philippa Whitford MP, tabled a question to ask the Secretary of State for Health and Social Care, what recent discussions their Department has had with (a) BEIS, (b) NIHR and (c) the MHRA about the UK’s ability to host large multi-site clinical trials for dementia.